小儿咳喘宁口服液治疗儿童急性支气管炎量效关系的临床观察

Clinical Observation of the Dose-effect Relationship of Pediatric Kechuanning Oral Liquid for Acute Bronchitis in Children

目的:观察不同剂量的小儿咳喘宁口服液治疗急性支气管炎风痰蕴肺证患儿的临床疗效,并探讨其量效关系。方法:将65例急性支气管炎风痰蕴肺证患儿随机分为低、中、高剂量组及对照组。对照组予常规治疗,低、中、高剂量组均在常规治疗基础上服用相应剂量的小儿咳喘宁口服液,疗程均为5天。比较4组患儿的呼吸道症状体征评分、中医证候评分及总体疗效的差异。结果:治疗5天后,中剂量组及高剂量组总有效率均为93.7%,与对照组(87.6%)比较,差异均有统计学意义(P <0.05)。低剂量组总有效率88.2%,与对照组比较,差异无统计学意义(P> 0.05)。低剂量组总有效率与高剂量组、中剂量组比较,差异均有统计学意义(P <0.05),但高剂量组与中剂量组比较,差异无统计学意义(P> 0.05)。4组呼吸道症状体征评分、中医证候评分治疗前后比较,差异均有统计学意义(P <0.05);低、中、高剂量组的呼吸道症状体征评分、中医证候评分均低于对照组,治疗前后积分差均高于对照组,差异均有统计学意义(P <0.05);中、高剂量组的呼吸道症状体征评分、中医证候评分均低于低剂量组,治疗前后积分差均高于低剂量组,差异均有统计学意义(P <0.05);中剂量组与高剂量组比较,差异无统计学意义(P>0.05)。结论:小儿咳喘宁口服液治疗儿童急性支气管炎风痰蕴肺证安全、有效,且存在"增量即增效"的量效关系。中剂量的疗效不亚于高剂量,因此可参照中剂量细化年龄段用量。

Objective： To observe the clinical effect of pediatric Kechuanning oral liquid in different doses for acute bronchitis in children with syndrome of wind-phlegm stagnating the lung, and discuss its dose-effect relationship. Methods： Divided 65 cases of children with acute bronchitis along with syndrome of wind-phlegm stagnating the lung into the low-dose group, the middle-dose group, the high-dose group and the control group randomly. The control group was given the routine treatment, while the low-dose group, the middle-dose group and the high-dose group additionally received the oral administration of pediatric Kechuanning oral liquid in corresponding doses. The treatment for all groups lasted for 5 days. Compared respiratory symptom scores, Chinese syndrome scores and the total clinical effect of children in the four groups. Results： After 5 days of treatment, the total effective rate was 93.7% in the middle-dose group and the high-dose group respectively, when comparing with the control group （87.6%）, there were significant differences being found（P 〈 0.05）. The total effective rate was 88.2% in the low-dose group, when comparing with the control group, there were no significant difference being found （P 〉 0.05）, when comparing with the middle-dose group and the high-dose group, there were significant differences being found（P 〈 0.05）. However, comparing the total effective rate in the high-dose group and that in the middle-dose group, there was no significant difference being found（P 〉 0.05）. Comparing the respiratory symptom scores and Chinese syndrome scores in the four groups before treatment with those after treatment, differences being significant （P 〈 0.05）; the respiratory symptom scores and Chinese syndrome scores in the low-dose group, the middle-dose group and the high-dose group were lower than those in the control group, and the difference of scores before treatment from those after treatment was higher than the control group, differences being significant（P 〈 0.05）; the respiratory symptom scores and Chinese syndrome scores in the middle-dose group and the high-dose group were lower than those in the low-dose group, and the difference of scores before treatment from those after treatment was higher than the low-dose group, differences being significant （P 〈 0.05）; comparing the middle-dose group with the high-dose group, there were no significant difference being found（P 〉 0.05）. Conclusion. Pediatric Kechuanning oral liquid can treat acute bronchitis in children with syndrome of wind-phlegm stagnating the lung safely and effectively, and there exists the dose-effect relationship of ＂the increase in dosage leads to the rise in efficacy＂ . The therapeutic effect of the middle dose is nothing less than the high dose, so the middle dose can be referred to as refinement of dosage in each age group.